Trials / Approved For Marketing
Approved For MarketingNCT04074512
Copper Histidinate Treatment for Menkes Disease
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Sentynl Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 0 Years – 6 Years
- Healthy volunteers
- —
Summary
This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | copper histidinate | copper histidinate for subcutaneous injection |
Timeline
- First posted
- 2019-08-30
- Last updated
- 2026-03-02
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04074512. Inclusion in this directory is not an endorsement.